Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 608-408-6 | CAS number: 29736-24-1
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
The substance is considered to be non-mutagenic in the bacterial reverse mutation test.
The bacterial reverse mutation test conducted with Salmonella typhimurium strains supports the conclusion that the substance is non-mutagenic at concentration from 0.01 to 5.0 mg/plate
The chromosome aberration test (in-vitro) shows chromosomal aberrations in cultured cells at a concentration of 5,000 µg/ml.
In the in-vivo mammalian erythrocyte micronucleus test none of the experimental groups treated with the test item showed an increase in MPCEs (micro-nucleated polychromatic erythrocytes). The test item is therefore considered to be non-mutagenic in the mouse bone marrow micronucleus test.
Based on these results, it can be concluded that the positive in vitro findings for chromosomal aberration are overruled by the overall weight of evidence of negative in vivo and other in vitro test for this endpoint.
Short description of key information:
Bacterial reverse mutation test (in-vitro): non-mutagenic
Chromosome Aberration Test (in-vitro): test item induces chromosomal aberrations in cultured cells at a concentration of 5000µg/ml
Mammalian Erythrocyte Micronucleus Test (in-vivo): non-mutagenic
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
The test item needs not to be classified since the positive in-vitro findings for chromosomal aberration are overruled by the overall weight of evidence of negative in- vivo and other in vitro tests.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
